TX-PLANVIEW
18.5.2022 15:02:10 CEST | Business Wire | Press release
Planview, a global leader in Portfolio Management and Work Management, today announced that the company has entered into a definitive agreement to acquire Tasktop, a pioneer and leader in Value Stream Management (VSM). Based in Vancouver, Canada, Tasktop has 200+ employees and in FY21 saw record growth with 43% year-over-year user expansion.
“As companies strive to differentiate, survive, thrive, and disrupt their markets, there is a surge in digitalization and transformation initiatives. While well-intended, the facts show that most digital transformation efforts fail to achieve value for the business,” said Razat Gaurav, Chief Executive Officer at Planview. “Together, we provide an exciting and much needed capability that will help our customers to connect the business of software delivery – enabling them to efficiently transform their organizations faster with more confidence, and a better ability to achieve desired business outcomes.”
“Connecting Planview’s leadership in enterprise Agile and strategic portfolio management with Tasktop’s leadership in VSM is a game-changing combination that expands the capabilities and value proposition we can offer to customers. Tasktop and Planview’s complementary offerings will better help our customers realize digital transformation – accelerating the pace at which they can transform and deliver competitive advantages through technology,” said Mik Kersten, Founder and Chief Executive Officer at Tasktop. “Tasktop and Planview have more than eight years of history working together, and we’re thrilled to be taking this next step in our relationship to join forces and make it possible for every organization to become a digital innovator.”
The acquisition of Tasktop is part of Planview’s strategy to build the future of connected work and deliver transformative solutions. Together, Planview and Tasktop will empower organizations to accelerate their time to market, improve operational efficiency and drive investment confidence in the face of economic disruption and instability. In the past year, Tasktop’s solutions have played a critical part of some of the world’s most successful digital transformations, including BMW, HSBC, Kaiser Permanente, T-Mobile and TUI Group. Similarly, Planview has added marquee global customers such as ADP, AT&T, IBM, FIFA, and Standard Chartered.
Leading industry analyst firms like Forrester1 point to the benefits of integrating Strategic Portfolio Management (SPM) and VSM. According to Forrester, “Building genuine business agility requires having the necessary information at hand to make pivot or persevere decisions. When SPM is integrated with delivery systems such as value stream management (VSM), it provides visibility into actual performance to support change decisions.”1
Upon completion of the transaction, the Tasktop team will join Planview, bringing additional expertise and thought leadership around VSM. Kersten will serve as Chief Technology Officer. The transaction is expected to close mid-Summer of 2022, pending regulatory approval. Terms of the transaction were not disclosed.
1 Forrester, Now Tech: Strategic Portfolio Management Tools, Q3 2021, Margo Visitacion, August 19, 2021.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com .
About Tasktop
Tasktop's value stream management platform enables enterprises to master software at scale. Leading brands, including half of the Fortune 100, use Tasktop to provide real-time visibility into the health of product value streams, allowing them to make better decisions and align with business goals. Tasktop connects with existing third party tools businesses are already using and overlays the end-to-end value stream to provide the abstractions, automations, visualizations and forensics needed to practice value stream management on a daily basis. Learn more about Tasktop at tasktop.com and follow us on Twitter @tasktop.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006293/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom